Multicenter cohort study of DNA methylation in risk populations of cervical cancer in Suzhou

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200063237

Enrollment

Unknown

Registered

2022-09-02

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Interventions

High-Risk HPV or TCT ASCUS+:None

Eligibility

Sex/Gender

Female

Age

22 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Age: unlimited; 2. With TCT, hr-HPV classification and colposcopic biopsy test results; 3. Patients with hr-HPV positive or/and TCT ASCUS+; 4. No immunodeficiency disease; 5. Willing to cooperate with doctors for follow-up treatment and follow-up investigation; 6. Sign an informed consent form voluntarily.

Exclusion criteria

Exclusion criteria: 1. Previous history of cervical cancer or other malignant tumors; 2. Previous genital warts; 3. Patients cannot correctly express their complaints, such as psychosis and severe neurosis; 4. Any other factors that the researcher considers to be unsuitable for the subject's entry into the study.

Design outcomes

Primary

Measure	Time frame
DNA Methylation;	—

Countries

China

Contacts

Public ContactYouguo Chen

The First Affiliated Hospital of Suzhou University

chenyouguo@suda.edu.cn+86 13901547463

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026